Bayer inks US$1.55bn cancer deal with Loxo...German Bayer AG has acquired ex-US commercialisation rights to Loxo Oncology Incs Phase II lead larotrectinib (LOXO-101), which targets TRK (tropomyosin receptor kinase) fusions in 17 cancer types, … more ➔
Bill Gates invests into Alzheimer’s... Billionaire Bill Gates announced he is going to invest US$50m private money into the Dementia Discovery Fund (DDF) to support fresh ideas for developing Alzheimer drugs and diagnostics. The venture … more ➔
CHMP recommends EU marketing approval of...The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval, including two orphan medicines, plus three generics at its November 2017 … more ➔
BIO-Europe more popular than ever More than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing – like the biotech industry itself. more ➔
Spain pushes circular bioeconomyConversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently … more ➔
Stem cells cure deadly human skin diseaseFor the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional … more ➔
InflaRx Announces Pricing of Initial Publi... German inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in … more ➔
FDA lifts clinical hold on Cellectis Phase...The US Food and Drug Administration (FDA) has lifted the clinical hold due to a patient death on Phase I testing of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm … more ➔
MAB Discovery expands 2013 partnership wit... German MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec. more ➔
European biotech stocks: New wave of optim...In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November … more ➔
